Parmax Pharma

{
  "main_header": {
    "sid": 1002724,
    "name": "Parmax Pharma",
    "stock_name": "Parmax Pharma",
    "full_name": "Parmax Pharma Ltd",
    "name_url": "stocks-analysis/parmax-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "32.76",
    "chg": -0.49,
    "chgp": "-1.47%",
    "dir": -1,
    "prev_price": "33.25",
    "mcapval": "12.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540359,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE240T01014",
    "curr_date": "Feb 12",
    "curr_time": "",
    "bse_nse_vol": "615 ",
    "exc_status": "Active",
    "traded_date": "Feb 12, 2026",
    "traded_date_str": "2026 02 12",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/parmax-pharma-1002724-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "When is the next results date for Parmax Pharma Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-parmax-pharma-ltd-3833797",
        "imagepath": "",
        "date": "2026-02-11 23:17:17",
        "description": "The next results date for Parmax Pharma Ltd is scheduled for 14 February 2026...."
      },
      {
        "title": "Parmax Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/parmax-pharma-ltd-is-rated-strong-sell-3771013",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ParmaxPharmaLtd_mojoScore_3771013.png",
        "date": "2025-12-26 15:13:06",
        "description": "Parmax Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 June 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 26 December 2025, providing investors with the latest comprehensive analysis."
      },
      {
        "title": "Why is Parmax Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-parmax-pharma-fallingrising-3764375",
        "imagepath": "",
        "date": "2025-12-20 02:32:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Current Market Performance and Price Movement</strong></p>\n<p>On 19 December, Parmax Pharma’s shares experienced a significant intraday decline, touching a low of ₹31.00, down ₹2.63 from the previous close. This drop represents an underperformance of 8.57% against its sector, with the weighted average price indicating that most trading volume occurred near the day’s low. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish trend and weak investor sentiment.</p>\n<p>Investor participation has also waned, with delivery volumes on 18 December falling by 27.84% compared to the five-day average, suggesting reduced confidence among shareholders. Despite adequate liquidity for trading, the stock’s downward moment..."
      },
      {
        "title": "Parmax Pharma’s Evaluation Revised Amidst Challenging Financial and Market Conditions",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/parmax-pharma-downgraded-to-strong-sell-amid-weak-fundamentals-and-bearish-outlook-3755153",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ParmaxPharma_mojoScore_3755153.png",
        "date": "2025-12-10 10:10:28",
        "description": "Parmax Pharma has undergone a revision in its market assessment reflecting a more cautious outlook due to recent financial and technical developments. The pharmaceutical company’s evaluation metrics have shifted downward, influenced by deteriorating fundamentals and market performance indicators."
      },
      {
        "title": "Parmax Pharma Stock Falls to 52-Week Low of Rs.28 Amidst Weak Financials",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parmax-pharma-stock-falls-to-52-week-low-of-rs-28-amidst-weak-financials-3731354",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ParmaxPharma_priceRelatedfactors_3731354.png",
        "date": "2025-11-26 11:49:41",
        "description": "Parmax Pharma's shares touched a fresh 52-week low of Rs.28 today, marking a significant decline amid subdued financial performance and persistent volatility. The stock's intraday fall of 10.26% outpaced the Pharmaceuticals & Biotechnology sector, reflecting ongoing challenges within the company’s fundamentals."
      },
      {
        "title": "How has been the historical performance of Parmax Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-parmax-pharma-3713235",
        "imagepath": "",
        "date": "2025-11-18 23:02:10",
        "description": "Answer:\nThe historical performance of Parmax Pharma shows significant fluctuations in key financial metrics over the years.\n\nBreakdown:\nParmax Pharma's net sales have seen a notable increase from Mar'24 at 11.05 Cr to Mar'25 at 28.20 Cr, following a dip in Mar'23 at 15.42 Cr and Mar'22 at 18.25 Cr. However, the total expenditure also rose sharply to 27.95 Cr in Mar'25 from 14.43 Cr in Mar'24, leading to a slim operating profit of 0.25 Cr in Mar'25, a recovery from a loss of 3.38 Cr in the previous year. Despite this, the company reported a profit before tax of -2.40 Cr in Mar'25, an improvement from -5.66 Cr in Mar'24, but still indicative of ongoing challenges. The profit after tax also remained negative at -2.09 Cr in Mar'25, although less severe than the -5.75 Cr recorded in Mar'24. The company's reserves have turned negative, dropping to -6.44 Cr in Mar'25 from -4.35 Cr in Mar'24, reflecting a deteriora..."
      },
      {
        "title": "How has been the historical performance of Parmax Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-parmax-pharma-3703972",
        "imagepath": "",
        "date": "2025-11-15 00:20:37",
        "description": "Answer:\nThe historical performance of Parmax Pharma shows significant fluctuations in its financial metrics over the years.\n\nBreakdown:\nParmax Pharma's net sales have seen a notable increase from INR 11.05 crore in March 2024 to INR 28.20 crore in March 2025, following a decline from INR 15.42 crore in March 2023 and INR 18.25 crore in March 2022. The total operating income mirrored this trend, rising to INR 28.20 crore in March 2025 from INR 11.05 crore in March 2024. However, the company's total expenditure also increased, reaching INR 27.95 crore in March 2025, up from INR 14.43 crore in March 2024. This led to an operating profit of INR 0.25 crore in March 2025, a recovery from a loss of INR 3.38 crore in March 2024. Despite this, the profit before tax remained negative at INR -2.40 crore in March 2025, although it improved from INR -5.66 crore in March 2024. The profit after tax also showed a loss of I..."
      }
    ],
    "total": 112,
    "sid": "1002724",
    "stock_news_url": "https://www.marketsmojo.com/news/parmax-pharma-1002724"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Consider And Approve Unaudited Financial Results For Quarter And Nine Months Ended On December 31 2025",
      "datetime": "09-Feb-2026",
      "details": "Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve Unaudited Financial results for quarter and nine months ended on December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "12-Jan-2026",
      "details": "RTA Certificate under regulation 74(5) of SEBI DP Regulations for quarter ended December 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "30-Dec-2025",
      "details": "Closure of trading window",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "14 Feb 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

When is the next results date for Parmax Pharma Ltd?

2026-02-11 23:17:17

The next results date for Parmax Pharma Ltd is scheduled for 14 February 2026....

Read full news article

Parmax Pharma Ltd is Rated Strong Sell

2025-12-26 15:13:06

Parmax Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 June 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 26 December 2025, providing investors with the latest comprehensive analysis.

Read full news article

Why is Parmax Pharma falling/rising?

2025-12-20 02:32:50

Current Market Performance and Price Movement

On 19 December, Parmax Pharma’s shares experienced a significant intraday decline, touching a low of ₹31.00, down ₹2.63 from the previous close. This drop represents an underperformance of 8.57% against its sector, with the weighted average price indicating that most trading volume occurred near the day’s low. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish trend and weak investor sentiment.

Investor participation has also waned, with delivery volumes on 18 December falling by 27.84% compared to the five-day average, suggesting reduced confidence among shareholders. Despite adequate liquidity for trading, the stock’s downward moment...

Read full news article

Parmax Pharma’s Evaluation Revised Amidst Challenging Financial and Market Conditions

2025-12-10 10:10:28

Parmax Pharma has undergone a revision in its market assessment reflecting a more cautious outlook due to recent financial and technical developments. The pharmaceutical company’s evaluation metrics have shifted downward, influenced by deteriorating fundamentals and market performance indicators.

Read full news article

Parmax Pharma Stock Falls to 52-Week Low of Rs.28 Amidst Weak Financials

2025-11-26 11:49:41

Parmax Pharma's shares touched a fresh 52-week low of Rs.28 today, marking a significant decline amid subdued financial performance and persistent volatility. The stock's intraday fall of 10.26% outpaced the Pharmaceuticals & Biotechnology sector, reflecting ongoing challenges within the company’s fundamentals.

Read full news article

How has been the historical performance of Parmax Pharma?

2025-11-18 23:02:10

Answer: The historical performance of Parmax Pharma shows significant fluctuations in key financial metrics over the years. Breakdown: Parmax Pharma's net sales have seen a notable increase from Mar'24 at 11.05 Cr to Mar'25 at 28.20 Cr, following a dip in Mar'23 at 15.42 Cr and Mar'22 at 18.25 Cr. However, the total expenditure also rose sharply to 27.95 Cr in Mar'25 from 14.43 Cr in Mar'24, leading to a slim operating profit of 0.25 Cr in Mar'25, a recovery from a loss of 3.38 Cr in the previous year. Despite this, the company reported a profit before tax of -2.40 Cr in Mar'25, an improvement from -5.66 Cr in Mar'24, but still indicative of ongoing challenges. The profit after tax also remained negative at -2.09 Cr in Mar'25, although less severe than the -5.75 Cr recorded in Mar'24. The company's reserves have turned negative, dropping to -6.44 Cr in Mar'25 from -4.35 Cr in Mar'24, reflecting a deteriora...

Read full news article

How has been the historical performance of Parmax Pharma?

2025-11-15 00:20:37

Answer: The historical performance of Parmax Pharma shows significant fluctuations in its financial metrics over the years. Breakdown: Parmax Pharma's net sales have seen a notable increase from INR 11.05 crore in March 2024 to INR 28.20 crore in March 2025, following a decline from INR 15.42 crore in March 2023 and INR 18.25 crore in March 2022. The total operating income mirrored this trend, rising to INR 28.20 crore in March 2025 from INR 11.05 crore in March 2024. However, the company's total expenditure also increased, reaching INR 27.95 crore in March 2025, up from INR 14.43 crore in March 2024. This led to an operating profit of INR 0.25 crore in March 2025, a recovery from a loss of INR 3.38 crore in March 2024. Despite this, the profit before tax remained negative at INR -2.40 crore in March 2025, although it improved from INR -5.66 crore in March 2024. The profit after tax also showed a loss of I...

Read full news article

View All News